FDA Clears Rivaroxaban (Xarelto) for Extended VTE Prevention FDA Clears Rivaroxaban (Xarelto) for Extended VTE Prevention

The agency approves rivaroxaban 10 mg once daily for reducing the ongoing risk for recurrent venous thromboembolism following at least 6 months of initial anticoagulation therapy.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Alert Source Type: news